Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 18/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3474823 | 0.88 | EPHX2 (0.79) | EPHX2CYP2C9POLBMAPT | |
| SCHEMBL2787489 | 0.87 | EPHX2 (0.79) | EPHX2CYP2C9 | |
| SCHEMBL3472485 | 0.84 | POLB (0.55) | EPHX2CYP2C9POLBMAPTLMNA | |
| SCHEMBL2259739 | 0.82 | EPHX2 (0.79) | EPHX2CYP2C9 | |
| SCHEMBL3471782 | 0.81 | EPHX2 (0.79) | EPHX2CYP2C9 | |
| SCHEMBL2258875 | 0.81 | EPHX2 (1.00) | EPHX2CYP2C9 | |
| SCHEMBL3474360 | 0.80 | EPHX2 (0.63) | EPHX2CYP2C9 | |
| SCHEMBL2259136 | 0.79 | EPHX2 (0.76) | EPHX2CYP2C9 | |
| SCHEMBL2790708 | 0.78 | EPHX2 (1.00) | EPHX2CYP2C9 | |
| SCHEMBL2260518 | 0.78 | EPHX2 (0.83) | EPHX2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
| EP-2240021-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009097474-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | EPHX1, NCEH1, PCSK9 | EPHX2 5/4885CYP2C9 201/4885POLB 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.